Effects of embryonic and neonatal disruption of developing central dopaminergic systems.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn; D003342:Corpus Striatum / Q000187:drug effects / Q000254:growth & development* / Q000378:metabolism; D003891:Desipramine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D006220:Haloperidol / Q000494:pharmacology; D006892:Hydroxydopamines / Q000494:pharmacology; D008124:Locomotion; D008781:Methyltyrosines / Q000494:pharmacology; D051381:Rats
D006892:Hydroxydopamines; D008781:Methyltyrosines; D015102:3,4-Dihydroxyphenylacetic Acid; D006220:Haloperidol; D003891:Desipramine; D004298:Dopamine